Fluidigm Launches Higher-Throughput BioMark; Will Discontinue First-Gen System by Year End | GenomeWeb

By Ben Butkus

Fluidigm this week announced the launch of the BioMark HD real-time PCR system and said that it will stop selling its previous-generation BioMark instrument by the end of this year.

According to Fluidigm, the new BioMark platform will have twice the throughput as its predecessor, enabling faster time to result and allowing customers to more easily perform large-scale single-cell gene expression studies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.